Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05433506 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of HU6
A Phase 1 study, sponsored by Rivus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT05433506 is a Phase 1 study that has completed, run by Rivus Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT05433506, a Phase 1 study, has completed, sponsored by Rivus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Twelve subjects will be randomized (1:1) to treatment sequence to determine the order in which they will receive the tablet or capsule formulation in Period 1 and Period 2. Part 2 is an open-label study of up to 4 single, ascending dose levels of HU6 administered as the tablet formulation. Eight subjects will be enrolled to participate in all of the ascending study periods.
Interventions
- DRUG HU6 Tablet
- DRUG HU6 Capsule
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-09-15 |
| Est. Completion | 2023-03-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05433506
The ClinicalTrials.gov registry entry for NCT05433506 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rivus Pharmaceuticals, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which HU6 Tablet is the first listed.
NCT05433506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05433506 about?
NCT05433506 is a clinical study titled "Safety and Pharmacokinetics of HU6". Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Twelve subjects will be randomized (1:1) to treatment sequence to determine the order in which they will receive the tablet or capsule formulation in Period 1 and Period 2. Part 2 is an open-label study of up to 4 single, ascend...
What is the current status of trial NCT05433506?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2022-09-15. Estimated completion is 2023-03-15.
What interventions are being tested in trial NCT05433506?
The interventions under investigation include: HU6 Tablet (DRUG), HU6 Capsule (DRUG).
Who is sponsoring clinical trial NCT05433506?
This trial is sponsored by Rivus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.